Company profile: SaNOtize
1.1 - Company Overview
Company description
- Provider of platform-based nitric oxide topical therapies for upper respiratory and dermal infections, including a Nitric Oxide Nasal Spray (NONS) that reduces respiratory viral RNA load within 24–72 hours, a physician-provided Foot Cleanser for plantar warts, and a Gel Cleanser for nails and skin in development, with additional cleansers and wellness products planned for US launch in 2025–2026.
Products and services
- Nitric Oxide Foot Cleanser: A physician-directed cleanser used in care regimens for plantar warts and other foot conditions, integrating nitric oxide chemistry for recommended foot care applications
- Nitric Oxide Gel Cleanser for Nails and Skin: An in-development gel employed in wellness regimens for infected nails or skin, aiming to improve care for nail fungus and similar dermal infections
- Nitric Oxide Nasal Spray (NONS™): An antiviral nasal spray shown effective against respiratory viruses, including COVID-19, significantly reducing viral RNA load within 24 to 72 hours of treatment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to SaNOtize
NanoView Biosciences
HQ: United States
Website
- Description: Provider of proprietary products supporting research, translation and delivery of precision medicine, built on a novel platform that uniquely identifies and characterizes exosomes. Offers high-throughput, cost-effective analysis, including Leprechaun for lentivirus and exosome biophysical characterization, contaminant detection, and concentration measurement using fluorescence and antibody-based methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NanoView Biosciences company profile →
Biotest Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceutical and biotherapeutic products utilized in immunology, with innovation in haematology, clinical immunology and intensive care medicine, incorporating innovative technologies and a sharp focus on safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotest Pharmaceuticals company profile →
DeepUll
HQ: Spain
Website
- Description: Provider of a biotech diagnostic system for early-stage sepsis that rapidly identifies pathogens and delivers an antibiogram within hours, leveraging patient immunological and functional data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DeepUll company profile →
OnCore Biopharma
HQ: United States
Website
- Description: Provider of biotechnology research, development, and commercialization of therapies for chronic hepatitis B virus (HBV) infection, assembling a portfolio of novel product candidates with unique mechanisms of action for the treatment of hepatitis B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnCore Biopharma company profile →
Accelerate Diagnostics
HQ: United States
Website
- Description: Provider of in vitro diagnostic solutions for drug-resistant organisms and hospital-acquired infections, offering the Accelerate Pheno System for rapid ID and AST of bloodstream infections from positive blood cultures; the Accelerate Arc System for automated ID directly from positive blood cultures; the Accelerate PhenoTest BC Kit used with the Pheno system for fast ID and susceptibility results; and Gel Electrofiltration for sample cleanup.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accelerate Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for SaNOtize
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to SaNOtize
2.2 - Growth funds investing in similar companies to SaNOtize
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for SaNOtize
4.2 - Public trading comparable groups for SaNOtize
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →